As China Dives Into RWE, J&J Teams Up To Tackle Depression
Executive Summary
A new tie-up between J&J and a Singapore startup portends a new chapter for China drug development, using real world data and associated evidence, as China moves to clarify RWE regulations.
You may also be interested in...
Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option
“There’s an app for that” could take on added significance under a new alliance for a digital therapeutic for the treatment of depression, in which the partners hope the novel approach will take its place as an effective option among current drug and other cognitive therapies.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.